





Pathfinder Wales: **Faster, further, and fairer**



Contents

▶ Foreword	3
▶ Key findings	5
▶ Awareness: further to go	6
▶ Diagnosis: a faster diagnostic pathway is possible	7
▶ Treatment: fairer access for all	10
▶ Support: missing for too many	12
▶ Recurrent ovarian cancer	14
▶ References	15



For the methodology used in this research please visit:
targetovariancancer.org.uk/pathfinder

Foreword

Ovarian cancer can be devastating and survival rates across the UK are among the worst in Europe. Over 300 women are diagnosed with ovarian cancer in Wales each year.¹ Just over a third of women in Wales are diagnosed at an early stage (stage I or II) where outcomes will be better.²

Target Ovarian Cancer was founded in 2008 to change this. One of the charity's key early priorities was to carry out the Pathfinder study to identify what is working and, critically, what needs to change to drive forward urgently needed improvements in survival and support. We carry out the Pathfinder study in Wales as well as across the UK.

Our Pathfinder Wales research is made up of three surveys:

- ▶ Awareness of symptoms in women in the general public in Wales.
- ▶ GPs in Wales.
- ▶ Women in Wales who were diagnosed with ovarian cancer between 2016 and 2022.

Sadly, 51 per cent of those diagnosed in Wales at stage IV will not survive for one year so many will not have had the chance to share their experiences through surveys like this.³ The experiences shared in this report must be read with this in mind.


We first carried out the Pathfinder study in Wales in 2016 and have seen some welcome areas of progress between 2016 and 2022 including:

- ▶ The establishment of a single cancer pathway in Wales for gynaecological cancers.

Over 300 women are diagnosed with ovarian cancer in Wales each year.

- ▶ The establishment of an ovarian cancer audit in England and Wales which will provide much needed data on how services are performing.
- ▶ Exciting progress in ovarian cancer treatment with the introduction of PARP inhibitors. Alongside this we have seen widespread use of genomic testing offering, for the first time, personalised medicine to those with some forms of ovarian cancer.

However, from March 2020 the Covid-19 pandemic had a significant impact across the health service and on ovarian cancer diagnosis and treatment. It is clear that while NHS Wales staff worked incredibly hard to minimise the disruption, we still have some way to go to recover. And as well as recover, now is the time to go further.



The Covid-19 pandemic had a significant impact on ovarian cancer diagnosis and treatment.

Key findings

Awareness

Awareness of ovarian cancer symptoms in the general population has shown some improvement since we first started measuring this in Wales in 2016. However, progress has been slow, and we have seen little improvement in awareness of urinary symptoms and the symptom of feeling full. Worryingly, 42 per cent of women in Wales wrongly believe that cervical screening detects ovarian cancer.

Diagnosis

The faster ovarian cancer is diagnosed, the greater the chance of receiving treatment and the greater the chance of survival. For the first time, we surveyed GPs' knowledge of symptoms unprompted and found good awareness of the symptoms of bloating and abdominal pain, which is welcome following Target Ovarian Cancer's investment in GP education programmes. However, we also found delays both in access to diagnostic tests and in GPs receiving results, as well as GPs needing more support to interpret test results. It is vital that existing guidelines are updated to provide GPs with the support they need to identify ovarian cancer as quickly as possible.

Treatment

Ovarian cancer treatment has changed significantly since 2016, with widespread access to new maintenance treatments and greater access to genomic testing enabling a more personalised approach to treatment. As genomic testing moves at a pace, it is vital that the consent process empowers patients to make the best choice for them. We also found that the pandemic may have had an impact on the opportunity to be involved in clinical trials in Wales.

Support

It is clear that support for those with ovarian cancer is lacking. We found high levels of unmet need including mental health support and support with menopause.

While our latest Pathfinder Wales findings show that we continue to make progress in the diagnosis, treatment, and support for those with ovarian cancer, they also show that there remains an urgent need – and ample opportunity – for this to be further, faster and fairer in order to achieve the world-class ovarian cancer outcomes for women in Wales that we all want.

Awareness: further to go

Everyone needs to know the symptoms of ovarian cancer.

With no effective screening tool, the main route to ovarian cancer being diagnosed is by women visiting their GP with symptoms. By knowing the symptoms to look out for, women are more likely to visit their GP sooner, increasing their chances of being diagnosed earlier.

This is the second time Target Ovarian Cancer has tracked awareness of the four key symptoms of ovarian cancer among women in the general population in Wales (Table 1).

It is encouraging to see improvement in awareness of bloating and abdominal pain which is evidence that increased awareness of ovarian cancer symptoms is possible if action is taken.

Despite awareness of symptoms tracking upwards since 2016, only six per cent of women surveyed said they were very confident in naming the symptoms. This is likely to mean that even if they spot something is not right, they might not make an appointment or seek advice.

We also found that a worrying 42 per cent of women in Wales wrongly believe that cervical screening detects ovarian cancer. This means that women may think that if their cervical screening was clear they are not at risk of developing ovarian cancer.

Table 1: Symptoms awareness among women in the general population in Wales

Symptom	2016	2022
Bloating	17%	27%
Abdominal pain	18%	33%
Feeling full	5%	3%
Urinary urgency	1%	2%

Recommendations

- ▶ There is an urgent need for a government funded awareness campaign across Wales that highlights the symptoms of ovarian cancer and encourages women with concerns to visit their GPs.
- ▶ The information provided at cervical screening appointments must make it clear it does not test or screen for other gynaecological cancers and include the symptoms of ovarian cancer.

Diagnosis:

a faster diagnostic pathway is possible

Faster diagnosis saves lives – the quicker the diagnosis is received, the more quickly treatment can begin.

The earlier a woman is diagnosed the greater her chance of survival: 93 per cent of women diagnosed at the earliest stage (stage I or II) survive for at least five years compared to just 13 per cent of women diagnosed at the most advanced stage (stage IV).⁴

In Wales, around a third of women are currently diagnosed at an early stage.⁵

We must go faster on diagnosis. Our research shows that there are still too many delays in the diagnostic pathway, and that GPs need more training and support.

Delays in getting tested

Those we surveyed reported delays in accessing tests and receiving their diagnosis:

- ▶ One quarter reported visiting their GP three or more times before being referred for tests.
- ▶ One third reported waiting more than three months from their first appointment with their GP to receiving their diagnosis.

Women who have been diagnosed also report having to wait before undergoing tests:

- ▶ 38 per cent say they waited eight days or more to have a CA125 blood test.
- ▶ 71 per cent say they waited eight days or more to have an ultrasound.

This is compounded by delays reported by GPs in how long it takes on average to get the results of an urgent non-obstetric ultrasound for suspected ovarian cancer:

- ▶ 54 per cent of GPs report it takes 15 days or more to receive results.
- ▶ This includes 17 per cent reporting waits of 32 days or more.

These results demonstrate that there are delays in both undergoing the tests and GPs getting the results, adding up to too long a wait to confirm or rule out ovarian cancer. It is clear that there must be greater investment in diagnostic capacity and the pathway must be shortened.

GP confidence and knowledge


GPs are the first port of call for someone experiencing symptoms. No GP wants to miss an ovarian cancer diagnosis, but our survey of GPs has found more practical support is needed.

For the first time we surveyed GPs in Wales on their knowledge of ovarian cancer symptoms unprompted (Figure 1).

We found that GPs had good knowledge of bloating and abdominal pain, but there are gaps in knowledge around other symptoms.

GPs would also benefit from education on key facts about ovarian cancer, with 43 per cent believing incorrectly that symptoms only present in the late stage of the disease.

Figure 1: GP awareness of key ovarian cancer symptoms




GPs also report needing more support with interpreting test results:

- ▶ 70 per cent of GPs are confident in interpreting CA125 test results.
- ▶ 57 per cent of GPs are confident in interpreting ultrasound results.

GPs report that they find it difficult to know when to re-test following a normal or nominally elevated CA125 blood test result. Some are unsure how to manage postmenopausal women who are displaying symptoms but have a normal or nominally elevated CA125.

For ultrasound, GPs said they would like a clear recommendation for further action alongside the descriptive report they receive with test results, and others wanted more clarity on next steps when the report says that the ovaries were not visualised.

New ways of working are also proving challenging with 70 per cent of GPs in Wales telling us they think remote consultations can hinder diagnosis. There is a clear need for support and best practice for GPs.



Recommendations

- ▶ Given the time taken to get the results of the CA125 blood test and urgent non-obstetric ultrasound in primary care, there is an urgent need to shorten the ovarian cancer diagnostic pathway in Wales with the CA125 blood test and ultrasound undertaken at the same time.
- ▶ There must be better support for GPs across Wales to interpret and act on ultrasound results.

Treatment: fairer access for all

Everyone with ovarian cancer deserves the best possible treatment, targeted to their needs.

We have seen major steps forward in treatment since 2016 with the introduction of PARP inhibitors – the biggest improvement in treatment options in almost 30 years. There remains more work to be done in improving access to clinical trials and surgery.

Access to clinical trials

Clinical trials offer women the opportunity to access experimental cancer drugs, improve understanding of the disease and treatment options, and access the highest quality care. They are also often the only way of accessing new treatment for those who have a rarer ovarian cancer tumour or those who have become resistant to the standard treatment regimen.

Figure 2: At any stage since diagnosis have you been asked by anyone involved in your treatment if you would like to join a clinical trial?

- ▶ 2022 Yes: 25 per cent
- ▶ 2016 Yes: 35 per cent

We found a 10 per cent decline in women in Wales being asked about clinical trials when compared to our Pathfinder Wales report in 2016 (Figure 2). This is despite a clear desire to take part in clinical trials with 61 per cent of respondents who had not taken part in a clinical trial wanting to do so and 78 per cent prepared to travel to a different hospital to take part in a trial.

A decline in clinical trials may be due to the lack of availability as a result of the Covid-19 pandemic. Urgent action needs to be taken to ensure that the decline in opportunities to take part in trials is reversed and information about appropriate trials is shared proactively with patients.

Genomic testing

Since our last Pathfinder report in 2016 the genomic testing landscape has radically changed, with ovarian cancer at the forefront of new developments.

The availability of some PARP inhibitors is dependent on the presence of a BRCA variation or HRD status.⁶ This means that genomic testing has a treatment implication for some women with ovarian cancer. The presence of a BRCA germline variant has implications for family members as they may also have the gene, so women need the right support when undergoing BRCA germline testing.

Of those we surveyed in Wales:

- ▶ 79 per cent had BRCA germline testing.
- ▶ 42 per cent had BRCA somatic testing.
- ▶ Eight per cent report HRD testing (available in the UK from December 2021).

However, 65 per cent said they weren't offered specialist counselling to help them decide if they wanted to be tested.

Access to surgery

Research has shown that treatment at a specialist multidisciplinary gynaecology cancer centre improves survival by 45 per cent.⁷ The data from our surveys did not give us enough detail to assess where surgery and other treatment was undertaken, or what proportion of women in Wales receive surgery.

We need to see better analysis of NHS Wales data to understand where and how surgery is being accessed and the impact that can have on survival. The forthcoming national audit of ovarian cancer in Wales should be able to provide more data on this.

Recommendations

- ▶ Patients must be empowered to ask about clinical trials, with signposting to information on clinical trials embedded into interactions between patients and their clinical team.
- ▶ We need to see urgent investment in post pandemic studies that will lead to better treatments.
- ▶ There must be a consistent approach to consenting for genomic testing with access, where required, to genetic counselling maintained for those having BRCA germline testing.
- ▶ Everyone that would benefit from specialist surgery must be able to access it no matter where they live in Wales.

Support: missing for too many

A diagnosis of ovarian cancer is devastating.

Alongside treatment for ovarian cancer, care and support is crucial to deal with challenges like side effects, the impact on mental health and reducing feelings of isolation. This should be available at the right time and in the right place, but too often those we surveyed report that this support is not readily accessible.

Getting support right from the start

It is vital that a diagnosis of ovarian cancer is delivered in the best possible way, personalised to the individual to empower them to make choices about their treatment, care and support. The gold standard for communicating a diagnosis is that it should be done privately, face to face (either in person or on video call) with enough time for questions and in the presence of a Clinical Nurse Specialist. Everyone should be signposted to an ovarian cancer specific charity or patient support organisation who can provide support.



Support should be available at the right time and in the right place, but too often it is not readily accessible.

However, our survey found significant variation:

- ▶ 41 per cent were not signposted to a charity or patient support organisation.
- ▶ 26 per cent felt they were not given enough time to discuss their diagnosis.
- ▶ 39 per cent said that a Clinical Nurse Specialist was not present when they got their diagnosis.

100 per cent of those surveyed reported they had access to a specialist cancer nurse, but 25 per cent said their specialist nurse was not always available to them.

Mental health

Aside from the physical implications of a diagnosis of ovarian cancer, having cancer and the treatment involved can impact on mental wellbeing:

- ▶ 75 per cent of those surveyed said having ovarian cancer had a negative impact on their mental health.
- ▶ Over half of those surveyed were never asked about the impact of their treatment on their mental health.
- ▶ Of those experiencing mental ill health as result of having ovarian cancer, 22 per cent reported they were not referred for support.

It is clear that there is an urgent need to better embed mental health support in the care and treatment received, from ensuring that it is asked about at every appointment, to having the services available to be referred to.

Taking a holistic approach to support

In addition to mental health needs, ovarian cancer can affect every area of life. Holistic support, where all the support needs are considered, is vital to maintaining quality of life (Table 2).

Table 2: In which of the following areas have you needed support since being diagnosed with ovarian cancer?

Getting life back on track after treatment	71%
Feelings of isolation	55%
Issues relating to body image	69%
Regaining sexual intimacy	67%

Clinical Nurse Specialists are key to the provision of support. Target Ovarian Cancer surveyed CNSs across the UK and found that they are overstretched with not enough time to provide for both medical and support needs of their patients. Tackling the support gap requires urgent investment in the CNS workforce.⁸

Recommendations

- ▶ There should be upscaling of capacity and funding to ensure that the very best support is offered to everyone.
- ▶ Diagnosis of ovarian cancer must always be made face to face, in private and with the right support, including a Clinical Nurse Specialist present.
- ▶ Everybody should be asked about their mental health and emotional wellbeing at every appointment, and services must be in place to support the mental health and wellbeing needs of everyone with an ovarian cancer diagnosis.
- ▶ The Clinical Nurse Specialist workforce are vital to providing support, so it is vital that there is investment into recruiting the next generation of CNSs. It is also crucial that the current workforce is retained and given opportunities for professional development.

Recurrent ovarian cancer

Around 70 per cent of those diagnosed with ovarian cancer will experience a recurrence, where the cancer returns after first line treatment.⁹

It is important that those who have finished first line treatment are equipped with the knowledge and support around recurrence, but our survey found that this is often not provided:

- ▶ 75 per cent said that signs and symptoms of recurrent ovarian cancer were not discussed with them.
- ▶ 74 per cent would have liked support coping with fear of recurrence.

Recommendation

- ▶ Those with a recurrence should have the same support as first line treatment and all those who have had first line treatment should have signs of recurrence discussed with them.

References

1. Public Health Wales (2022) Cancer Incidence in Wales, 2002–2019. Available at: [Cancer Incidence in Wales, 2002–2019 – Public Health Wales. Available at: phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2019/](https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2019/)
2. Ibid
3. Public Health Wales (2022) Cancer Survival in Wales, 2002–2019. Available at: <https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-survival-in-wales-2002-2019/>
4. Office for National Statistics (2019) Cancer Survival in England: adults diagnosed between 2013 and 2017 and followed up to 2018. Available at: ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancersurvivalratescancersurvivalinenglandadultsdiagnosed
5. Public Health Wales (2022) Cancer Incidence in Wales, 2002–2019. Available at: [Cancer Incidence in Wales, 2002–2019 – Public Health Wales. Available at: phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2019/](https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2019/)
6. targetovariancancer.org.uk/about-ovarian-cancer/treatment/targeted-treatments-ovarian-cancer
7. Khoja, L., et al. 'Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK'. *Clinical Oncology* (Royal College of Radiologists (Great Britain)), vol. 28, no. 12, Dec. 2016, pp. 760–65. PubMed, <https://doi.org/10.1016/j.clon.2016.06.011>.
8. Target Ovarian Cancer (2022) *Pathfinder 2022: faster, further and fairer*. Available at: targetovariancancer.org.uk/pathfinder
9. Giornelli, Gonzalo H. 'Management of Relapsed Ovarian Cancer: A Review'. *SpringerPlus*, vol. 5, no. 1, July 2016, p. 1197. PubMed Central, <https://doi.org/10.1186/s40064-016-2660-0>.

About Target Ovarian Cancer

At Target Ovarian Cancer, we target what's important to stop ovarian cancer devastating lives.

We give trusted information, to help people ask questions and make decisions that are right for them. We connect people with shared experiences, and we support families every step of the way.

We stand together as a powerful community for everyone facing ovarian cancer across the UK, sharing stories and raising voices to make sure that ovarian cancer becomes a health priority.

We know that early diagnosis saves lives, so we work closely with GPs who are at the heart of this to help them diagnose ovarian cancer faster and earlier – giving everyone the best chance of living.

And our investment in research to find new, better and more targeted treatments means that everyone can live with hope for their future.

We're fighting for a world where everyone with ovarian cancer lives, and we're targeting what's important – symptoms awareness, early diagnosis, better treatments, and support for all.



✉ 30 Angel Gate, London, EC1V 2PT

☎ 020 7923 5470

@ info@targetovariancancer.org.uk

🖱 targetovariancancer.org.uk

f TargetOvarianCancer

🐦 @TargetOvarian

📷 @TargetOvarian



Target Ovarian Cancer is a company limited by guarantee, registered in England and Wales (No. 6619981).

Registered office: 30 Angel Gate, London EC1V 2PT.

Registered charity numbers 1125038 (England and Wales) and SC042920 (Scotland).

© 2023 Target Ovarian Cancer. All Rights Reserved